Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -86.5%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $5M | $3M | $6M | $4M | $7M | $8M | $465300 | $9M | $2M | $54M |
| Enterprise Value | $-4008110 | $-2537844 | $-2520632 | $3M | $-4155416 | $-3544442 | $9M | $1M | $9M | $2M | $53M |
| P/E Ratio → | -0.49 | — | — | — | — | 0.39 | — | — | — | — | — |
| P/S Ratio | 533.34 | 778.38 | 310.89 | 721.02 | 47.01 | 81.81 | 48.96 | 2.81 | 71.80 | 322.73 | — |
| P/B Ratio | 0.39 | 0.62 | 0.54 | 0.63 | 0.26 | 0.70 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -422.97 | -229.15 | 335.81 | -46.90 | -40.39 | 53.16 | 8.69 | 74.84 | 426.85 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | -0.15 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.4% | 63.4% | 60.0% | 60.0% | 67.8% | 45.4% | 69.2% | 72.5% | 43.4% | -66.7% | — |
| Operating Margin | -102380.2% | -102380.2% | -52216.9% | -62445.9% | -11562.5% | -3562.2% | -677.7% | -682.9% | -895.7% | -24537.6% | — |
| Net Profit Margin | -99916.8% | -99916.8% | -49940.7% | -58739.7% | -11449.3% | 21892.8% | -22082.2% | -5126.1% | -10977.2% | -55398.1% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -86.5% | -86.5% | -65.8% | -40.3% | -77.8% | 188.0% | — | — | — | — | — |
| ROA | -82.8% | -82.8% | -63.2% | -35.4% | -66.6% | 320.6% | -5818.7% | -1683.3% | -4014.6% | -1011.7% | -474.7% |
| ROIC | -1284.0% | -1284.0% | -118.4% | -58.5% | -218.3% | — | — | — | — | — | — |
| ROCE | -88.6% | -88.6% | -68.8% | -42.9% | -78.6% | -30.6% | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -0.94 | -0.34 | -0.52 | -1.05 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | 5.49 | -28.54 | -3.48 | -9.03 | -3.12 | -118.74 |
Net cash position: cash ($7M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 25.97 | 25.97 | 18.73 | 27.65 | 5.64 | 10.22 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Quick Ratio | 25.97 | 25.97 | 18.72 | 27.64 | 5.64 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Cash Ratio | 25.30 | 25.30 | 18.13 | 26.89 | 5.54 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.23 | 0.31 | 0.26 | 0.02 | — |
| Inventory Turnover | — | — | 2.01 | 0.55 | 2.79 | 4.41 | — | — | — | — | — |
| Days Sales Outstanding | — | 3168.44 | — | — | — | 10.34 | — | 12.35 | 28.17 | 365.08 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 253.8% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.3% | 0.2% | 5.1% | 4.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.2% | 5.1% | 4.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $1M | $1M | $1M | $324861 | $57946 | $2068 | $1203 | $153 | $140 |
Binary clinical trial failure
Based on reported figures, CELZ trades at a P/S multiple of 516.13, which suggests that the market is pricing the firm as a speculative call option on its intellectual property rather than a business with any meaningful current revenue generation or predictable growth trajectory.
The extreme valuation multiple relative to the negligible $6,000 TTM revenue indicates that investors are ignoring traditional fundamental metrics in favor of potential clinical trial outcomes. This pricing suggests that any failure to achieve regulatory milestones could lead to a rapid and severe contraction in market capitalization.
According to historical financial statements, CELZ has consistently reported negative ROIC figures, with the most recent quarter showing -3.0%, reflecting a structural inability to generate returns on invested capital that exceed the cost of maintaining its extensive research and administrative overhead.
The persistent negative returns on capital suggest that the company is currently destroying shareholder value rather than compounding it. Without a transition to a high-volume commercial model, these metrics imply that the firm will continue to rely on dilutive financing to sustain its operations.
As reported in recent filings, the company's DPO has fluctuated wildly, reaching as high as 23,965 days in 2025Q4, which indicates an unstable and highly irregular approach to managing supplier obligations in the absence of a consistent, scaled commercial revenue stream.
The lack of meaningful asset turnover, which remains near zero, confirms that the company is not currently utilizing its balance sheet to drive operational output. Investors should monitor these efficiency metrics for signs of stabilization, though current trends suggest a lack of operational maturity.
Based on the provided balance sheet data, CELZ maintains a current ratio of 19.69 as of 2026Q1, which appears superficially strong but is primarily a function of the company's cash-heavy position relative to its minimal operational liabilities and lack of commercial scale.
While the current liquidity position provides a temporary buffer against insolvency, it does not reflect operational health or the ability to generate self-sustaining cash flow. The reliance on this cash pile to fund ongoing R&D suggests that the company remains in a vulnerable state of perpetual capital consumption.
The P/S ratio is the most commonly misapplied metric for CELZ, as it obscures the company's pre-commercial status and fails to account for the binary nature of its regenerative medicine pipeline, which is not yet reflected in the negligible top-line revenue figures.
Using revenue-based multiples for a firm with only $6,000 in TTM sales is fundamentally flawed and provides no insight into the company's actual value. Analysts should instead focus on cash runway and clinical milestone progression as more appropriate indicators of the firm's survival and potential upside.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CELZ stock.
Creative Medical Technology Holdings, Inc.'s current P/E ratio is -0.5x. The historical average is 0.4x.
Creative Medical Technology Holdings, Inc.'s return on equity (ROE) is -86.5%. The historical average is -63.1%.
Based on historical data, Creative Medical Technology Holdings, Inc. is trading at a P/E of -0.5x. Compare with industry peers and growth rates for a complete picture.
Creative Medical Technology Holdings, Inc. has 63.4% gross margin and -102380.2% operating margin.